Proposed Agenda & Faculty, 3-4 November 2023
Welcome and Introduction, Ryan Fitzpatrick, Joana Torres & Millie Long
Session I: Optimizing Biologic Therapies in IBD
Anti-TNF therapy in IBD (including biosimilars)
Joana Torres, Hospital Beatriz Ângelo & Hospital da Luz, Portugal
Anti-integrin therapy in IBD
Henit Hanay, Rabin Medical Center, Petah Tikva, Israel
IL-23 therapies in IBD
Triana Lobaton, Ghent University Hospital, Ghent, Belgium
Session II: Focus on small molecules in IBD
Conventional immunomodulator therapy in IBD – still a role in the armamentarium?
Naila Arebi, St. Mark’s Hospital, Harrow, Middlesex, UK
JAK Inhibitors in IBD: Does selectivity matter?
Séverine Vermeire, Leuven, Belgium
S1P Inhibitors in IBD – how do they work and how to use them?
Britta Siegmund, Universitätsmedizin Berlin, Berlin, Germany
Independent Expert Discussion with food
Session III: Women’s health in IBD
Contraceptive and Pre-Conception Counseling in IBD: the role of the Gastroenterologist
Marla C. Dubinsky, Icahn School of Medicine Mount Sinai New York
Pregnancy and IBD
Mette Julsgaard, Aarhus University Hospital, Aarhus, Denmark
Post Delivery: Implications for Mum and Baby
Sophie Restellini, Hôpital de La Tour, Switzerland
Session IV: Medical and surgical management of IBD
Chairs: Millie Long & Joana Torres
Non-invasive monitoring of IBD
Federica Furfaro, Istituto Clinico Humanitas IRCCS
Treat to Target in IBD – too much or too little?
Ana Guttierrez, Hospital General Universitario de Alicante
Surgical Management of the female IBD patient
Susana Ourô, Hospital Beatriz Ângelo & Hospital da Luz, Portugal